Form 4 · Filed May 20, 2026, 08:29 PM UTC
ACRV/Acrivon Therapeutics, Inc.
Blume-Jensen Peter — President and CEO
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
2 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026 | A | other | 180,095 | $0 | — | 2,259,046 |
| May 18, 2026 | A | other | 72,706 | $0 | — | 386,343 |
Source: SEC EDGAR raw filing ↗ · Accession 0000905148-26-002549